个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共12条记录   Angiogenesis-related molecular targets in esophageal cancer [作者：Hong, L; Li, SJ; Han, Y; Du, JJ; Zhang, HW; Li, JP; Zhao, QC; Wu, KC; Fan, DM,期刊：Expert opinion on investigational drugs, 页码：637-644 , 文章类型： Review，,卷期：2011年20-5] Introduction: Angiogenesis has become an appealing target in cancer therapy due to its fundamental role in cancer growth and metastasis. A number of angiogenesis-related molecules are under investigation, with some alrea... HIF prolyl hydroxylase inhibitors for anemia [作者：Muchnik, E; Kaplan, J,期刊：Expert opinion on investigational drugs, 页码：645-656 , 文章类型： Review，,卷期：2011年20-5] Introduction: The hypoxia-inducible factor (HIF) system mediates the body's response to hypoxia, locally, inducing angiogenesis and a shift to anaerobic metabolism, and systemically, increasing red cell mass in anemia. H... The Syk kinase as a therapeutic target in leukemia and lymphoma [作者：Efremov, DG; Laurenti, L,期刊：Expert opinion on investigational drugs, 页码：623-636 , 文章类型： Review，,卷期：2011年20-5] Introduction: The B-cell receptor (BCR) delivers antigen-dependent and -independent signals that have been implicated in the pathogenesis of several common B-cell malignancies. Agents that can efficiently block BCR signa... Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia [作者：Tack, J; Janssen, P,期刊：Expert opinion on investigational drugs, 页码：701-712 , 文章类型： Editorial Material，,卷期：2011年20-5] Introduction: Functional dyspepsia (FD) is a highly prevalent condition with a major impact on quality of life and high socio-economic and healthcare costs. To date, no treatment of established efficacy in FD is availabl... Inhaled phosphodiesterase type 5 inhibitors for cystic fibrosis: a new therapy for systemic disease? [作者：Antoniu, SA,期刊：Expert opinion on investigational drugs, 页码：713-715 , 文章类型： Editorial Material，,卷期：2011年20-5] Cystic fibrosis is a rare disease characterized by abnormalities in chloride and sodium transmembrane transportation due to various mutations in the cystic fibrosis transmembrane regulator (CFTR) gene, F508del being the ... Pomalidomide therapy for myeloma [作者：Schey, S; Ramasamy, K,期刊：Expert opinion on investigational drugs, 页码：691-700 , 文章类型： Editorial Material，,卷期：2011年20-5] Introduction: The Office of National Statistics (London, UK) has reported 4040 new patients in the year 2007, with an annual age standardized incidence rate of 4.8 per 100,000 population (range 4.7-5.0). Overall survival... New targeted therapies for gastric cancer [作者：Asaoka, Y; Ikenoue, T; Koike, K,期刊：Expert opinion on investigational drugs, 页码：595-604 , 文章类型： Review，,卷期：2011年20-5] Introduction: Inhibitors targeting oncogenic kinases, especially receptor tyrosine kinases (RTKs), are being vigorously developed, and some have been demonstrated to be effective in clinical settings. The amplification o... Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer [作者：Buck, E; Mulvihill, M,期刊：Expert opinion on investigational drugs, 页码：605-621 , 文章类型： Review，,卷期：2011年20-5] Introduction: The IGF-1 receptor (IGF-1R) is a receptor tyrosine kinase and is well established as a key regulator of tumor cell growth and survival. There is also a growing body of data to support a role for the structu... From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer [作者：Gomez-Raposo, C; Mendiola, M; Barriuso, J; Hardisson, D; Redondo, A,期刊：Expert opinion on investigational drugs, 页码：591-594 , 文章类型： Editorial Material，,卷期：2011年20-5] Epithelial ovarian carcinoma (EOC) is the most important cause of gynecological cancer-related mortality in Western societies. The majority of patients with ovarian cancer present with advanced disease, and in this group... Novel agents for diffuse large B-cell lymphoma [作者：Sinha, R; DeJoubner, N; Flowers, C,期刊：Expert opinion on investigational drugs, 页码：669-680 , 文章类型： Review，,卷期：2011年20-5] Introduction: Although diffuse large B-cell lymphoma (DLBCL) is commonly considered as a cancer with a high cure rate with conventional therapies recent studies demonstrate that different biological variants of DBLCL exi... Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers? [作者：Steed, HL; Chu, QSC,期刊：Expert opinion on investigational drugs, 页码：681-690 , 文章类型： Editorial Material，,卷期：2011年20-5] Introduction: Endometrial cancer generally presents as early and resectable disease, but about 20% of patients present with either incurable or recurrent/metastatic disease. Patients with good performance status will be ... Lysophosphatidic acid-1-receptor targeting agents for fibrosis [作者：Rancoule, C; Pradere, JP; Gonzalez, J; Klein, J; Valet, P; Bascands, JL; Schanstra, JP; Saulnier-Blache, JS,期刊：Expert opinion on investigational drugs, 页码：657-667 , 文章类型： Review，,卷期：2011年20-5] Introduction: The presence of fibrosis is associated with alterations in organ architecture and is responsible for the morbidity of diseases including pneumopathies, systemic sclerosis, liver cirrhosis, chronic cardiovas...